Graft-versus-host disease (GVHD) is a common side effect of an allogeneic transplant (transplant using donor cells) that can affect many organs. This presentation describes how GVHD can affect the gut, and strategies to prevent and treat it.

Half of patients who have a stem cell transplant using donor cells (an allogeneic transplant) develop chronic graft-versus-host-disease (GVHD). In up to a third of those patients, GVHD affects the mouth, esophagus, stomach and/or GI tract. GVHD can also affect the liver and/or pancreas. This presentation describes the symptoms and treatment options for GI and liver GVHD.

Graft-versus-host disease (GVHD) frequently affects the gastrointestinal tract and liver after a stem cell transplant using donor cells (allogenic transplant). There are two types of GVHD: acute and chronic. This presentation discusses the incidence, symptoms, risk factors for each and treatment options.

The overall health of the gut microbiome and its organisms can influence the prevalence and severity of graft-versus-host disease. This presentation reviews the causes and mechanisms of how organisms in the gut can affect GVHD and reviews potential strategies to minimize this problem.

Graft-versus-host disease (GVHD) is a condition that can occur after a stem cell using donor cells (an allogenic transplant). This presentation describes how GVHD can affect the mouth, esophagus, stomach, small intestine, large intestine and liver.